← Back to Search

Education Materials and Janssen Test for Shortness of Breath

N/A
Waitlist Available
Led By John W Peabody, MD PhD
Research Sponsored by Qure Healthcare, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights

Study Summary

This trial will study how U.S. cardiologists and pulmonologists manage patients with unexplained chronic shortness of breath, and how a new Janssen Pharmaceuticals test affects clinical decision making.

Eligible Conditions
  • Shortness of Breath
  • Unexplained Chronic Breathlessness

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
CPV-measured clinical score difference
CPV-measured cost difference
Test Adoption Rate
Secondary outcome measures
CPV-measured baseline variation
CPV-measured clinical score differences by use case
CPV-measured cost differences by use case

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Educational Materials and Janssen Test Results when Selected (Intervention 2)Experimental Treatment1 Intervention
Participants will care for the same set of CPV patients as the control arm, but will be educated on and will receive the Janssen test results only if they select it. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
Group II: Educational Materials and Janssen Test Results (Intervention 1)Experimental Treatment1 Intervention
Participants will care for the same set of CPV patients as the control arm, but will be educated on and will receive the Janssen test results whether they select it or not. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
Group III: ControlActive Control1 Intervention
These providers will complete two rounds of three simulated patient cases (CPVs). Control arm physicians will continue to have access to standard of care diagnostic tools, but not the Janssen test results.

Find a Location

Who is running the clinical trial?

Qure Healthcare, LLCLead Sponsor
21 Previous Clinical Trials
3,736 Total Patients Enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Industry Sponsor
514 Previous Clinical Trials
844,440 Total Patients Enrolled
Janssen Pharmaceutical Companies of Johnson & JohnsonUNKNOWN

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Health Policy and PlanningJournal
A Novel Method for Measuring Health Care System Performance: Experience from QIDS in the Philippines
Solon, O., K. Woo, S. A Quimbo, R. Shimkhada, J. Florentino, and J. W Peabody. 2009. “A Novel Method for Measuring Health Care System Performance: Experience from QIDS in the Philippines”. Health Policy and Planning. Oxford University Press (OUP). doi:10.1093/heapol/czp003.
Population Health ManagementJournal
Engaging Primary Care Providers to Reduce Unwanted Clinical Variation and Support ACO Cost and Quality Goals: A Unique Provider-payer Collaboration
Burgon, Trever B., James Cox-Chapman, Catherine Czarnecki, Robert Kropp, Richard Guerriere, David Paculdo, and John W. Peabody. 2019. “Engaging Primary Care Providers to Reduce Unwanted Clinical Variation and Support ACO Cost and Quality Goals: A Unique Provider-payer Collaboration”. Population Health Management. Mary Ann Liebert Inc. doi:10.1089/pop.2018.0111.
Plos OneJournal
Clinical Utility of a Comprehensive, Whole Genome CMA Testing Platform in Pediatrics: A Prospective Randomized Controlled Trial of Simulated Patients in Physician Practices
Peabody, John, Megan Martin, Lisa DeMaria, Jhiedon Florentino, David Paculdo, Michael Paul, Rena Vanzo, E. Robert Wassman, and Trever Burgon. 2016. “Clinical Utility of a Comprehensive, Whole Genome CMA Testing Platform in Pediatrics: A Prospective Randomized Controlled Trial of Simulated Patients in Physician Practices”. Edited by Umberto Simeoni. Plos One. Public Library of Science (PLoS). doi:10.1371/journal.pone.0169064.
PLoS ONEJournal
Impact of Rheumatoid Arthritis Disease Activity Test on Clinical Practice
Peabody, John W., Vibeke Strand, Riti Shimkhada, Rachel Lee, and David Chernoff. 2013. “Impact of Rheumatoid Arthritis Disease Activity Test on Clinical Practice”. Edited by Oliver Frey. Plos ONE. Public Library of Science (PLoS). doi:10.1371/journal.pone.0063215.
~54 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top